本帖最后由 老马 于 2012-1-13 21:20 编辑
: t3 T& ^0 }) w% A- U0 F B8 A* V
4 Y9 v9 f8 m2 m' y; ] F" o- G爱必妥和阿瓦斯丁的比较
; @ _7 M: p, K1 s0 D$ L
+ r' g. p J( C$ _* F, Khttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
9 O3 |) Y) t/ F2 M7 [1 X0 M
( A4 [; i' }6 m# u0 [
2 G! ?0 Y: E4 [" S: @, zhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
( ]" ?9 |# ~) l* f==================================================
; z" b4 w# ?+ e( M% AOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)9 ]$ ]9 H9 D+ }) k
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.! `6 n# F' N4 O0 H: T5 C
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 }1 }6 R7 H& u
|